Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Improvement in Postoperative PAIN OUTcome (PAIN-OUT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Germany,United Kingdom,Germany,Sweden,Switzerland,Spain,Germany,Germany,Romania,United Kingdom,France,Israel,Germany,Germany,Italy,Sweden
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2012-12-31
Duration (months): 48.0
Total project cost (EUR): 3829100.0
EU funding (EUR): 2912325.0
Participants: 18
Project status: CLOSED

The main objective of the proposed project is to develop and to validate a system for measurement and feedback of outcome quality and support of decision making. The project will be executed in the areas of postoperative pain management which serves as an example for other fields of medicine with a high variation of care. The project will provide the medical community with a unique, user-friendly system to improve treatment of patients with postoperative pain. We propose to develop and implement a web-based information system, featuring three functions: Feedback and benchmarking system which provides participating sites with continuously updating data and analyses about the quality of care they provide compared to other institutions and allows identification of ‘best clinical practice’. Clinical Decision Support System for Post-Operative Pain, which responds to queries made by physicians for advice regarding treatment of individual patients. A Knowledge Library which provides clinicians with easily accessible summaries of evidence-based recommendations tailored to specific post-operative situations. The first two functions will draw their information from a large database or registry. The registry will receive data about post-operative patients from x participating clinical sites across Europe. The third function, the Knowledge Library, will draw its information from published, peer-reviewed studies, and will be updated periodically. To increase the benefit of the system to end-users, the registry will be complemented with patient data on side effects and treatment costs. All of these will be integrated into the feedback system. The proposed project is the first comprehensive, concerted European effort in the field of improving clinical decision making. It integrates experience gained from national initiatives, and the expertise of world-leading, European-based, groups dealing with benchmarking, health outcomes and health care utilization research

Keywords: clinical decision support,postoperative pain,benchmarking
Sensory and Biomechanical Markers in Diabetic Neuropathy of the Gut. Basic Investigations and New Approaches for Treatment (DIAMARK)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Denmark,Sweden,Denmark,Hungary,Ireland
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-11-01
End date: 2011-10-31
Duration (months): 36.0
Total project cost (EUR): 2270334.0
EU funding (EUR): 1776000.0
Participants: 6
Project status: CLOSED

DIAMARK is focused on analysing the pathophysiology of diabetic neuropathy and to determine better biomarkers of the complications and approaches for intervention. Due to lack of standardisation, there are no accepted biomarkers to evaluate the neuropathy and its involvement in the GI tract. Diabetes mellitus (DM) is one of the most common endocrine disorders affecting almost 6% (app. 246 million people) worldwide (http://www.idf.org). DM is a chronic disease requiring lifelong attention in order to limit the development of potentially devastating complications and to manage them if they occur. Gastrointestinal (GI) disorders are common and closely associated with autonomic neuropathy. Several studies addressed the visceral sensory function in DM and demonstrated abnormalities in perception thresholds, vagal tone and evoked brain potentials in patients with autonomic neuropathy. Thus, DM-related changes may be located in the enteric, the peripheral and in the CNS. Several clinical, neurophysiological and biochemical test for neuropathy have been proposed but they are not reliable and valid. This makes is crucial to develop better biomarkers for GI neuropathy and associated complications, to test the reliability and validity under controlled circumstances using advanced multimodal methods and to follow the biomarkers during new treatments. This proposal aims at determining new biomarkers related to the enteric nervous system (response to stimulation), peripheral nerves (recordings from visceral nerves) and central nervous system (evoked brain potentials and computation of the brain sources activated). After reliability testing under controlled circumstances in the laboratory and the clinic, the validity of the biomarkers will be followed during the most promising new treatments with gastric pacing and bypass surgery. The highly skilled academic and industrial partners of the consortium are selected based on their work on various aspects of the proposed framework.

Keywords: diabetes,neuropathy,visceral sensation,multimodal approach,gastric pacing,stenting
Novel Approaches to Bacterial Target Identification, Validation and Inhibition (NABATIVI)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,United Kingdom,Germany,Switzerland,France,Denmark,Sweden
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-02-01
End date: 2013-07-31
Duration (months): 54.0
Total project cost (EUR): 7131835.6
EU funding (EUR): 5506000.0
Participants: 10
Project status: CLOSED

Despite the advent of the antibiotic era, infectious diseases retain their pre-eminent position as major worldwide causes of morbidity and mortality. This problem has been worsen by the emergence of multi-antibiotic resistant bacteria and the failure of Pharmaceutical company drug discovery programmes to design antibiotics with truly novel modes of action. NABATIVI has put together a unique consortium made of six academic insitutions and three highly recognized SMEs with complementary expertise in the fields of molecular pathogenicity and broad expertise in drug discovery, optimisation, preclinical development. The consortium has been specifically designed to generate new strategies leading to the identification and validation of novel targets for antimicrobials using as model organisms the gram-negatives Pseudomonas aeruginosa and Burkholderia cenocepacia as they are key agents of morbidity and mortality worldwide in a wide range of diseases. The versatility of these model bacteria will enable the results obtained to be extrapolated to other bacterial pathogens. The extensive involvement of SMEs in this consortium will enable the selection of lead compounds against the identified targets from their large libraries of natural and synthetic chemicals which after validation will establish the basis for the development of new classes of antibacterial drugs. This will result in a reduction in the incidence and improvement of the treatment of infections caused by these organisms with a direct impact on the quality of life and the life expectancy of the affected risk patient populations.

Keywords: gram negative bacteria,antimicrobial resistance,novel drug target,lead compound,antibacterial
Search for new therapeutic agents against complicated obesity by reprofiling existing drugs (REPROBESITY)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Spain,France,Germany,Italy,Spain,Spain
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-12-01
End date: 2012-05-31
Duration (months): 42.0
Total project cost (EUR): 6946279.6
EU funding (EUR): 5399412.0
Participants: 7
Project status: CLOSED

Obesity is one of the most serious and fast-growing health problem in the European Union, and a leading cause of diabetes. The main barrier for approval of an anti-obesity drug is the safety requirements. We propose to overcome this barrier by discovering phenotypes and biomarkers that identify subsets of patients with safe and efficacious responses to drugs, and by identifying new indications of existing drugs with proven safety profiles. To be approved, anti-obesity drugs need to show a decrease in abdominal fat. We focus on approaches targeting directly abdominal fat cells. In the last years only the cannabinoid CB1 receptor antagonist Rimonabant has been approved as a therapeutic agent to combat complicated obesity. Research performed with this drug has clearly revealed a role for the endogenous cannabinoid system in controlling energy homeostasis. However, its utility is limited to a restricted set of patients. A new phenotype and/or biomarker may identify responsive patients with good safety profiles. This proposal aims to discover novel or improved treatments in the shortest possible timeframe through three synergistic Specific Aims: 1) Clinical phenotyping of obese patients to identify those that would benefit from existing therapies such as Rimonabant. 2) Discover biomarkers for subsets of obese patients that may correlate with therapeutical outcomes. These biomarkers will be discovered by a novel approach called Combinatorial Cytomic Biomarkers developed by OrphaMed, applied to cells from two physiologically interlinked sources: blood and abdominal-fat samples, extracted from the above phenotyped patients. 3) Identify new indications of existing drugs, alone or in combination, with potential anti-obesity efficacy by lowering the fat content and the glucose uptake of abdominal fat cells, which would be expected to improve carbohydrate/lipid metabolism and lower body weight, extracted from the above phenotyped patients. This will be accomplished by screening approximately 2.000 known drugs against these fat cells using the novel technology platform “ExviTech” from OrphaMed. Candidates would be evaluated in animal models of obesity.

Keywords: reprofiling anti-obesity drugs,obesity biomarkers,combinational cytomic biomarkers
E-Infrastructure for Testing, Integration and Configuration of Software - Phase 2 (ETICS 2)

Framework: FP7 — Capacities
Programme: Research Infrastructures
Destination: Support to existing research infrastructures
Action type: Combination of CP & CSA
Countries involved: Switzerland,Italy,Hungary,United States,Germany,Germany
Call:  (FP7-INFRASTRUCTURES-2007-2, 2007)
Start date: 2008-03-01
End date: 2010-02-28
Duration (months): 24.0
Total project cost (EUR): 3783568.0
EU funding (EUR): 2672000.0
Participants: 8
Project status: CLOSED

E-Infrastructures are one of the key enablers for large-scale scientific research and the development of Information Society in Europe. Scientific software and the middleware components providing grid services act as the framework for many scientific developments. Different and incompatible implementations of the services, disconnected and short-lived software repositories, lack of clear procedures for software build, test, validation and maintenance hinder the widespread adoption of grid technologies by many diverse communities. The definition and widespread adoption of common software lifecycle management procedures, manageable validation testbeds, distributed and federated repositories of code and software packages and widely agreed quality assurance processes and tools are goals closely aligned with an overall policy of creating a structural and sustainable eInfrastructure in Europe. The ETICS 2 project aims at supporting the widespread adoption of grid technologies by promoting and expanding the use of grid-based software engineering technologies by existing and new communities. The major objectives of the project are to provide an integrated combination of new key technologies (test management and workflow tools, release management tools, resource virtualization) and actively involve existing and new grid infrastructures through collaborations with key organizations and scientific research projects. In addition, ETICS 2 will build upon international collaborations in Europe and internationally through its direct links with parallel initiatives and infrastructures in the US and will directly support the emerging National Grid Initiatives (NGIs) creating a flexible, stable and reliable environment that can eventually be transitioned in the future, sustainable European Grid Initiative and used to establish official “quality labels” for grid software and create trust between users and providers.

Keywords: grid,software engineering,quality assurance,interoperability,software repositories
Signalling network regulating tooth development (TOOTH)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: European Re-integration Grants
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Hungary
Call:  (FP7-PEOPLE-2007-2-2-ERG, 2007)
Start date: 2008-04-01
End date: 2011-03-31
Duration (months): 36.0
Total project cost (EUR): 45000.0
EU funding (EUR): 45000.0
Participants: 1
Project status: CLOSED

In teeth sequential and reciprocal interactions between epithelium and ectomesenchyme play a pivotal role in their development. A progress has been made in identifying various key transcription factors and signalling molecules participating in epithelial–mesenchymal signalling, involving different pleiotropic morphogens, such as bone morphogenetic proteins, fibroblast growth factors, hedgehog and Wnt proteins as well, which are responsible for patterning, morphogenesis and differentiation. There is a growing interest in different stem cell niches located in tooth germs and how they provide cues for the maintenance, proliferation and differentiation of dental cells. The rodent incisor has a unique property: it exhibits asymmetric growth and enamel distribution due to the presence of discrete stem cell compartments at the apical part. The main research goal is to identify different key signalling molecules that regulate stem cell proliferation in the rodent incisor epithelial stem cell niche. As a former MC EIF fellow, I learned the details of in situ hybridization, tissue culture plus bead implantation assays, cell proliferation analyzes combined with different imaging techniques, digital densitometry, therefore we are planning to analyze mouse tooth development using all of these techniques to elucidate how the spatial and temporal expression pattern of these signalling molecules affects epithelial stem cell nice of incisor development. Additionally our aim is to characterize the stem cells molecularly and to develop methods for their isolation. We hope that our findings will have significant implications for organ regeneration and should prove of great interest to scientists in the fields of biology, medicine. The long-lasting benefit of my ERG is to adaptate these molecular morphological techniques at my host institution. The instrumental and scientific background is avaiable at host available, therefore it is possible to properly carry out the studies proposed.

Keywords: health sciences,odontology,developmental biology,tooth development
Feedback design for wireless networked systems (FEEDNETBACK)

Framework: FP7 — Cooperation
Programme: Information and Communication Technologies
Destination: Components, systems, engineering
Action type: Collaborative project
Countries involved: France,Switzerland,Spain,Sweden,Italy,France,France,United Kingdom,Hungary,United Kingdom
Call:  (FP7-ICT-2007-2, 2007)
Start date: 2008-09-01
End date: 2012-01-31
Duration (months): 41.0
Total project cost (EUR): 3756750.0
EU funding (EUR): 2900000.0
Participants: 11
Project status: CLOSED

Revolutionary developments in microelectronics over the past decades have led to the production of cheap yet powerful devices that communicate with one another, sense and act on their environment and are deployed in large numbers to deliver an abundance of data. Such devices and the networks they form (wireless sensor networks) bring together communication, computation, sensing and control and have enabled monitoring and automation at an unprecedented scale. Specially challenging in this context are networked control systems, where feedback control loops are closed over networked. To take full advantage of this technology novel design methods are necessary to transcend the traditional borders between disciplines, to apply the principles of feedback to complex, interconnected systems. The objective of the FEEDNETBACK project is to generate precisely such a co-design framework, to integrate architectural constraints and performance trade-offs from control, communication, computation, complexity and energy management. This will allow the development of more efficient, robust and affordable networked control technologies that scale and adapt with changing application demands. By focusing on wirelessly connected networks, we will study networked control from a fundamental point of view. We will extend the current scientific state-of-the-art in networked control and will develop a software tool set to support our co-design framework. To demonstrate and evaluate this framework, we will apply it to two industrial case studies: a smart camera network for surveillance and motion capture, and an underwater inspection system that comprises autonomous surface and underwater vehicles In addition to the impact in these two application areas, the new technologies in FEEDNETBACK will be disseminated through an ambitious program led by an innovation accelerator company, with the objective of linking the project’s research advances to market opportunities.

Keywords: networked controlled systems,feedback sensor networks,control and communication co-design.
Image-based Multi-scale Physiological Planning for Ablation Cancer Treatment (IMPPACT)

Framework: FP7 — Cooperation
Programme: Information and Communication Technologies
Destination: Towards sustainable and personalised healthcare
Action type: Collaborative project
Countries involved: Germany,Austria,Germany,Finland,United Kingdom,Ireland
Call:  (FP7-ICT-2007-2, 2007)
Start date: 2008-09-01
End date: 2011-12-31
Duration (months): 40.0
Total project cost (EUR): 4551188.0
EU funding (EUR): 3463367.0
Participants: 8
Project status: CLOSED

IMPPACT will develop an intervention planning and monitoring application for Radiofrequency Ablation (RFA) of malignant liver tumours. RFA is a minimally invasive form to treat cancer without open surgery, by placing a needle inside the malignancy and destroying it through intensive heating. Though the advantages of this approach are obvious, the intervention is currently hard to plan, almost impossible to monitor or assess, and therefore is not the first choice for treatment. IMPPACT will develop a physiological model of the liver and simulate the intervention’s result, accounting for patient specific physiological factors. Gaps in the understanding of particular aspects of the RFA treatment will be closed by multi-scale studies on cells and animals. New findings will be evaluated microscopically and transformed into macroscopic equations. The long-established bio-heat equation will be extended to incorporate multiple scales. Validation will be performed at multiple levels. Images from ongoing patient treatment will be used to cross check validity for human physiology. Final validation will be performed at macroscopic level through visual comparison of simulation and treatment results gathered in animal studies and during patient treatment. This extensive validation together with a user-centred software design approach will guarantee suitability of the solution for clinical practice. The consortium consists of two Hospitals, three Universities, one Research Institute and one industrial SME. The final project deliverables will be the patient specific intervention planning system and an augmented reality training simulator for the RFA intervention.

Keywords: physiological patient-specific modelling,multi-scale validation,liver,radio-frequency ablation,multi-modal image processing,augmented reality
Industrial Research Monitoring and Analysis (IRMA)

Framework: FP7 — Capacities
Programme: Support for the coherent development of research policies
Destination: Support for the coherent development of research policies
Action type: Coordination and support actions
Countries involved: European organisations area
Call:  (FP7-Adhoc-2007-13, 2007)
Start date: 2008-01-01
End date: 2012-07-31
Duration (months): 55.0
Total project cost (EUR): 6877135.2
EU funding (EUR): 5189870.0
Participants: 1
Project status: CLOSED

The Work Programme emphasises the need to ensure the continuation of the industrial research and innovation monitoring activities undertaken by the Commission. This proposal focuses on the collection of data and information on private companies and their use for gaining more insight in the reasons why firms are investing in research. It aims to provide policymakers with a better understanding of the returns to R&amp;D and of what measures are needed to remove the barriers to a wider use of R&amp;D. The Industrial R&amp;D Investment Scoreboard has become a standard reference for business and policymakers and will continue to be produced as part of this proposal. It will be accompanied by a regular survey of companies on R&amp;D developments. A concise digest of the literature and the results of specific studies will appear annually in the Economic and Policy Analysis Report. The 2nd European Conference on Corporate R&amp;D, to be held in 2009, will be an opportunity for policymakers and researchers to identify avenues for further investigation and to discuss the policy implications.

Keywords: innovation